drugset / Trial / NCT02049905
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
Timeline
- Start
- 2014-01
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldoxorubicin | Small molecule | 350 mg/m2 | Intravenous |
| Comparator | Dacarbazine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 900 mg/m2 | Intravenous |
| Comparator | Ifosfamide | Small molecule | 2 g | Intravenous |
| Comparator | Pazopanib | Small molecule | 800 mg | Oral |